Peran Analgesik Nonsteroidal Anti-inflammatory Drugs (NSAIDs) dan Analgesik Non-NSAIDs dalam Penanganan Nyeri

Jan S. Purba

doi:10.56951/medicinus.v35i1.90

Peran Analgesik Nonsteroidal Anti-inflammatory Drugs (NSAIDs) dan Analgesik Non-NSAIDs dalam Penanganan Nyeri

Penulis

Jan S. Purba Departemen Neurologi, Fakultas Kedokteran Universitas Indonesia/ RSUPN Cipto Mangunkusumo Jakarta

DOI:

https://doi.org/10.56951/medicinus.v35i1.90

Kata Kunci:

NSAID, nyeri kronis

Abstrak

Nyeri merupakan pengalaman sensorik dan emosional yang tidak menyenangkan, yang berhubungan dengan kerusakan jaringan aktual atau potensial, atau yang digambarkan dalam istilah kerusakan tersebut. Pengalaman nyeri berfungsi sebagai salah satu mekanisme perlindungan tubuh yang paling penting. Memahami mekanisme nyeri sangat penting bagi setiap dokter karena nyeri adalah masalah global yang melampaui semua spesialisasi medis. Nyeri yang menetap atau berkembang dalam jangka waktu yang lama disebut sebagai nyeri kronis. Berbeda dengan nyeri akut yang muncul tiba-tiba sebagai respons terhadap cedera tertentu, nyeri kronis bertahan dari waktu ke waktu dan seringkali resistan terhadap perawatan medis. Tujuan dari manajemen nyeri adalah untuk meredakan gejala dan meningkatkan tingkat fungsi individu dalam melakukan aktivitas sehari-hari. Sejumlah jenis obat telah digunakan dalam pengelolaan nyeri kronis.

Unduhan

Baca Selengkapnya

Referensi

Merksey H, Bogduk N (eds). Classification of chronic pain: description of chronic pain syndromes and definition of pain terms, 2nd edition. Seattle: International Association for the Study of Pain (IASP); 1994.

Loeser JD. MD Pain: The Fifth Vital Sign. APS Bulletin 2003:13.

Spitzer WO. Scientific approach to the assessment and management of activity-related spinal disorders: a monograph for clinicians. Report of the Quebec Task Force on spinal disorders. Spine 1987;12(Supp):S1-59. DOI: https://doi.org/10.1097/00007632-198709001-00001

Centers for Disease Control and Prevention. Acute Low Back Pain. Available at https://www.cdc.gov/acute-pain/low-back-pain/index.html cited April 1, 2022.

Deyo RA. Non-operative treatment of low back disorders. In: Frymoyer JW (Ed.). The Adult Spine: Principles and Practice. New York, NY: Raven Press, 1991.

Bigos S, Bowyer O, Braen G, et al. Acute low back problems in adults. Clinical practice guideline 14.AHCRP Publication No. 95-0642. Rockville, MD: Agency for Health Care Policy and Research, Public Heart Service, US Department of Health and Human Services, 1994.

Gow P. Acute low back pain. In: Rowbotham DJ and Macintyre PE (eds.). Clinical Pain Management. Acute Pain, London, Arnold 2003:pp.405-18. DOI: https://doi.org/10.1093/bja/aeg535

GBD 2016 Disease and Injury Incidence and Prevalence Collaborators, Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. The Lancet 2017;390(10100):1211–59.

Vargas C, Bilbeny N, Balmaceda C, et al., Costs and consequences of chronic pain due to musculoskeletal disorders from a health system perspective in Chile. Pain Rep. 2018;3(5):e656. DOI: https://doi.org/10.1097/PR9.0000000000000656

Osumili B, McCrone P, Cousins S, and Ridsdale L. The economic cost of patients with migraine headache referred to specialist clinics. Headache 2018;58:287–94. DOI: https://doi.org/10.1111/head.13210

Graven-Nielsen T and Arendt-Nielsen L. Assessment of mechanisms in localized and widespread musculoskeletal pain. Nat Rev Rheumatol. 2010;6(10):599-606. DOI: https://doi.org/10.1038/nrrheum.2010.107

Smart KM, Blake C, Staines A, Doody C. Clinical indicators of 'nociceptive', 'peripheral neuropathic' and 'central' mechanisms of musculoskeletal pain. A Delphi survey of expert clinicians. Man Ther 2010;15:80-7. DOI: https://doi.org/10.1016/j.math.2009.07.005

Świeboda P, Filip R, Prystupa A, Drozd M. Assessment of pain: types, mechanism and treatment. Pain. 2013;2(7).

Nachemson A. Latest knowledge of low back pain: a critical look. Clin Orthop and Related Res 1992;279:8-20. DOI: https://doi.org/10.1097/00003086-199206000-00003

Van Tulder M, Koes BW, Assendelft WJJ, Bouter LM (eds). The effectiveness of conservative treatment of acute and chronic LBP. Amsterdam: EMGO Institute, 1999.

Van Tulder M. Low Back Pain: Summery of systematic review and clinical guidelines. Refresher Course Syllabus, Giamberardino A M (ed.), IASP Press, Seattle 2002: pp.267-70.

McCleane GJ. Does gabapentin have an analgesic effect on background, movement and referred pain? A randomized, double-blind, placebo controlled study. Pain Clinic 2001;13:103-7. DOI: https://doi.org/10.1163/156856901753420945

Siddall PJ, Cousins MJ, Otte A, et al. Pregabalin in central neuropathic pain associated with spinal cord injury. Neurology 2006;67:1792-800. DOI: https://doi.org/10.1212/01.wnl.0000244422.45278.ff

Yildimir K, Sisecioglu M, Karatay S, et al. The effectiveness of gabapentin in patient with chronic radiculopathy. The Pain Clinic 2003;15:213-8. DOI: https://doi.org/10.1163/156856903767650718

Gallagher RM. Management of neuropathic pain: translating mechanistic advances and evidence-based research into clinical practice. Clin J Pain 2006;22:S2–8. DOI: https://doi.org/10.1097/01.ajp.0000193827.07453.d6

Jackson KC, Onge EL. Antidepressant pharmacotherapy: considerations for the pain clinician. Pain Pract 2003;3:135–43. DOI: https://doi.org/10.1046/j.1533-2500.2003.03020.x

Goucke CR. The management of persistent pain. Med J Aust 2003;178:444-7. DOI: https://doi.org/10.5694/j.1326-5377.2003.tb05287.x

Birbara CA, Puopolo AD, Munoz DR, et al. Treatment of chronic low back pain with etoricoxib, a new cyclo-oxygenase-2 selective inhibitor: improvement in pain and disability—a randomized, placebocontrolled, 3-month trial. J Pain 2003;4:307–15. DOI: https://doi.org/10.1016/S1526-5900(03)00633-3

Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med. 2000;343:1520–8. DOI: https://doi.org/10.1056/NEJM200011233432103

Brooks P, Kubler P. Etoricoxib for arthritis and pain management. Therapeutics and Clinical Risk Management 2006;2:45–57.

Liu W, Loo CC, Chiu JW, Tan HM, Ren HZ, Lim Y. Analgesic efficacy of pre-operative etoricoxib for termination of pregnancy in an ambulatory centre. Singapore Med J 2005;46:397-400.

Brooks PM and Day RO. Nonsteroidal antiinflammatory drugs differences and similarities. N Eng J Med 1991;324:1716-25. DOI: https://doi.org/10.1056/NEJM199106133242407

Insel PA. Anaagesic-antipyretics and antiinflammatory agents; drugs employed in the treatment of rheumatoid arthritis and gout. In: Gilman AG, Rall TW, Nies AS et al. (eds). Good man and Gilman's the pharmacological basis of therapeutics. 8th ed. V. 1. Singapore: McGraw-Hill Inc, 1992: pp.638-81.

Alon E, Niv D, Varrasi G, et al. Nonsteroidal anti-inflammatory drugs in the control of postoperative pain. Pain Digest 1996;6:145-52.

Dahl JB, Kehlet H. Non-steroid anti-inflammatory drugs: rational for use in severe postoperative pain. Br J Anasth 1991;66:703-12. DOI: https://doi.org/10.1093/bja/66.6.703

Zarghi A and Arfae S. Selective COX-2 Inhibitors: A Review of Their Structure-Activity Relationships. Iran J Pharm Res. 2011;10(4):655–83.

Urban MK. COX-2 specific inhibitors offer improved advantages over traditional NSAIDs Orthopedics 2000;23(7 Suppl):S761-4. DOI: https://doi.org/10.3928/0147-7447-20000702-05

Schaffer D, Florin T, Eagle C, et al. Risk of serious NSAID-related gastrointestinal events during long-term exposure: A systematic review. Med J Aust. 2006;185(9):501–6. DOI: https://doi.org/10.5694/j.1326-5377.2006.tb00665.x

Rahme E, Nedjar H. Risks and benefits of COX-2 inhibitors vs non-selective NSAIDs: Does their cardiovascular risk exceed their gastrointestinal benefit? A retrospective cohort study. Rheumatology (Oxford) 2007;46(3):435–8. DOI: https://doi.org/10.1093/rheumatology/kel428